Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Review

Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis

Authors: Leandro Luongo de Matos, Adriana Braz Del Giglio, Carolina Ogawa Matsubayashi, Michelle de Lima Farah, Auro Del Giglio, Maria Aparecida da Silva Pinhal

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background

To distinguish between malignant and benign lesions of the thyroid gland histological demonstration is often required since the fine-needle aspiration biopsy method applied pre-operatively has some limitations. In an attempt to improve diagnostic accuracy, markers using immunocytochemistry and immunohistochemistry techniques have been studied, mainly cytokeratin-19 (CK-19), galectin-3 (Gal-3) and Hector Battifora mesothelial-1 (HBME-1). However, current results remain controversial. The aim of the present article was to establish the diagnostic accuracy of CK-19, Gal-3 and HBME-1 markers, as well as their associations, in the differentiation of malignant and benign thyroid lesions.

Methods

A systematic review of published articles on MEDLINE and The Cochrane Library was performed. After establishing inclusion and exclusion criteria, 66 articles were selected. The technique of meta-analysis of diagnostic accuracy was employed and global values of sensitivity, specificity, area under the summary ROC curve, and diagnostic odds ratio (dOR) were calculated.

Results

For the immunohistochemistry technique, the positivity of CK-19 for the diagnosis of malignant thyroid lesions demonstrated global sensitivity of 81% and specificity of 73%; for Gal-3, sensitivity of 82% and specificity of 81%; and for HBME-1, sensitivity of 77% and specificity of 83%. The association of the three markers determined sensitivity of 85%, specificity of 97%, and diagnostic odds ratio of 95.1. Similar results were also found for the immunocytochemistry assay.

Conclusion

This meta-analysis demonstrated that the three immunomarkers studied are accurate in pre- and postoperative diagnosis of benign and malignant thyroid lesions. Nevertheless, the search for other molecular markers must continue in order to enhance this diagnostic accuracy since the results found still show a persistency of false-negative and false-positive tests.

Virtual slides

Http://www.diagnosticpathology.diagnomx.eu/vs/3436263067345159
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.CrossRefPubMed
2.
Gonzalez-Yebra B, Peralta R, Gonzalez AL, Ayala-Garcia MA, de Zarate ME O, Salcedo M: Genetic alterations in a primary medullary thyroid carcinoma and its lymph node metastasis in a patient with 15 years follow-up. Diagn Pathol. 2012, 7: 63-10.1186/1746-1596-7-63.PubMedCentralCrossRefPubMed
3.
Peccin S, de Castsro JA, Furlanetto TW, Furtado AP, Brasil BA, Czepielewski MA: Ultrasonography: is it useful in the diagnosis of cancer in thyroid nodules?. J Endocrinol Invest. 2002, 25: 39-43.CrossRefPubMed
4.
Tomimori EK, Bisi H, Medeiros-Neto G, Camargo RY: Ultrasonographic evaluation of thyroid nodules: comparison with cytologic and histologic diagnosis. Arq Bras Endocrinol Metabol. 2004, 48: 105-113.CrossRefPubMed
5.
Utiger RD: The multiplicity of thyroid nodules and carcinomas. N Engl J Med. 2005, 352: 2376-2378. 10.1056/NEJMp058061.CrossRefPubMed
6.
Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med. 1998, 338: 297-306. 10.1056/NEJM199801293380506.CrossRefPubMed
7.
LiVolsi VA, Baloch ZW: Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol. 2004, 11: 279-287. 10.1097/01.pap.0000138143.34505.02.CrossRefPubMed
8.
Zeiger MA, Dackiw AP: Follicular thyroid lesions, elements that affect both diagnosis and prognosis. J Surg Oncol. 2005, 89: 108-113. 10.1002/jso.20186.CrossRefPubMed
9.
Matsuo SE, Martins L, Leoni SG, Hajjar D, Ricarte-Filho JC, Ebina KN, Kimura ET: Biological markers in thyroid tumors. Arq Bras Endocrinol Metabol. 2004, 48: 114-125.CrossRefPubMed
10.
Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA: Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol. 2006, 17: 225-234. 10.1385/EP:17:3:225.CrossRefPubMed
11.
Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, Livolsi VA, Mandel SJ, et al.: Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. N Engl J Med. 2012, Epub ahead of print
12.
Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A: Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006, 6: 31-10.1186/1471-2288-6-31.PubMedCentralCrossRefPubMed
13.
Jones CM, Athanasiou T: Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005, 79: 16-20. 10.1016/j.athoracsur.2004.09.040.CrossRefPubMed
14.
Hong Z, Qi JP, Wang YW, Song YJ, Zhang ZY: Hyalinizing trabecular tumor and papillary carcinoma of the thyroid. Chin Med J (Engl). 2010, 123: 2832-2835.
15.
Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X: Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol. 2010, 63: 786-789. 10.1136/jcp.2010.076901.CrossRefPubMed
16.
Park YJ, Kwak SH, Kim DC, Kim H, Choe G, do Park J, Jang HC, Park SH, Cho BY, Park SY: Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci. 2007, 22: 621-628. 10.3346/jkms.2007.22.4.621.PubMedCentralCrossRefPubMed
17.
Scognamiglio T, Hyjek E, Kao J, Chen YT: Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006, 126: 700-708. 10.1309/044V86JN2W3CN5YB.CrossRefPubMed
18.
Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL: Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006, 19: 1631-1637. 10.1038/modpathol.3800705.CrossRefPubMed
19.
Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT: Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005, 18: 48-57. 10.1038/modpathol.3800235.CrossRefPubMed
20.
Cameron BR, Berean KW: Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma. J Otolaryngol. 2003, 32: 319-322. 10.2310/7070.2003.11429.CrossRefPubMed
21.
Casey MB, Lohse CM, Lloyd RV: Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003, 14: 55-60. 10.1385/EP:14:1:55.CrossRefPubMed
22.
Erkilic S, Aydin A, Kocer NE: Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol. 2002, 13: 207-211. 10.1385/EP:13:3:207.CrossRefPubMed
23.
Sahoo S, Hoda SA, Rosai J, DeLellis RA: Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001, 116: 696-702. 10.1309/6D9D-7JCM-X4T5-NNJY.CrossRefPubMed
24.
Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL: Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001, 14: 338-342. 10.1038/modpathol.3880312.CrossRefPubMed
25.
Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO: Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol. 2010, 21: 80-89. 10.1007/s12022-010-9114-y.CrossRefPubMed
26.
Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, Jones SJ, Griffith OL: Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol. 2008, 15: 2811-2826. 10.1245/s10434-008-0034-8.CrossRefPubMed
27.
Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW: Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol. 2008, 158: 375-384. 10.1530/EJE-07-0492.CrossRefPubMed
28.
Murphy KM, Chen F, Clark DP: Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol. 2008, 39: 420-426. 10.1016/j.humpath.2007.07.015.CrossRefPubMed
29.
Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV: Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol. 2006, 17: 213-223. 10.1385/EP:17:3:213.CrossRefPubMed
30.
Rossi ED, Raffaelli M, Mule A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G: Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology. 2006, 48: 795-800. 10.1111/j.1365-2559.2006.02428.x.CrossRefPubMed
31.
Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005, 12: 305-317. 10.1677/erc.1.00944.CrossRefPubMed
32.
Beesley MF, McLaren KM: Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002, 41: 236-243. 10.1046/j.1365-2559.2002.01442.x.CrossRefPubMed
33.
Song Q, Wang D, Lou Y, Li C, Fang C, He X, Li J: Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 2011, 6: 126-10.1186/1746-1596-6-126.PubMedCentralCrossRefPubMed
34.
Rydlova M, Ludvikova M, Stankova I: Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008, 152: 53-59. 10.5507/bp.2008.008.CrossRefPubMed
35.
Raggio E, Camandona M, Solerio D, Martino P, Franchello A, Orlandi F, Gasparri G: The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions. J Endocrinol Invest. 2010, 33: 378-381.CrossRefPubMed
36.
Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A, Maeda M, Miyoshi E, Kinoshita N, Yoshida H, et al.: Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun. 2008, 376: 605-610. 10.1016/j.bbrc.2008.09.041.CrossRefPubMed
37.
Aiad HA, Kandil MA, Asaad NY, El-Kased AM, El-Goday SF: Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst. 2008, 20: 36-46.PubMed
38.
Sapio MR, Guerra A, Posca D, Limone PP, Deandrea M, Motta M, Troncone G, Caleo A, Vallefuoco P, Rossi G, et al.: Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer. 2007, 14: 1089-1097. 10.1677/ERC-07-0147.CrossRefPubMed
39.
Aron M, Kapila K, Verma K: Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Indian J Pathol Microbiol. 2006, 49: 376-380.PubMed
40.
Ito Y, Nakamura Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, et al.: Polo-like kinase 1 expression in medullary carcinoma of the thyroid: its relationship with clinicopathological features. Pathobiology. 2005, 72: 186-190. 10.1159/000086788.CrossRefPubMed
41.
de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS: Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005, 47: 391-401. 10.1111/j.1365-2559.2005.02221.x.CrossRefPubMed
42.
Galusca B, Dumollard JM, Lassandre S, Niveleau A, Prades JM, Estour B, Peoc'h M: Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch. 2005, 447: 18-23. 10.1007/s00428-005-1268-5.CrossRefPubMed
43.
Nucera C, Mazzon E, Caillou B, Violi MA, Moleti M, Priolo C, Sturniolo G, Puzzolo D, Cavallari V, Trimarchi F, Vermiglio F: Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest. 2005, 28: 106-112.CrossRefPubMed
44.
Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR: The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004, 122: 524-531. 10.1309/UUQTE505PTN5QJ7M.CrossRefPubMed
45.
Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, Stern Y: Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck. 2004, 26: 960-966. 10.1002/hed.20087.CrossRefPubMed
46.
Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, Papotti M: Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. 2004, 445: 183-188.CrossRefPubMed
47.
Torres-Cabala C, Panizo-Santos A, Krutzsch HC, Barazi H, Namba M, Sakaguchi M, Roberts DD, Merino MJ: Differential expression of S100C in thyroid lesions. Int J Surg Pathol. 2004, 12: 107-115. 10.1177/106689690401200203.CrossRefPubMed
48.
Kovacs RB, Foldes J, Winkler G, Bodo M, Sapi Z: The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol. 2003, 149: 449-453. 10.1530/eje.0.1490449.CrossRefPubMed
49.
Jakubiak-Wielganowicz M, Kubiak R, Sygut J, Pomorski L, Kordek R: Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. Pol J Pathol. 2003, 54: 111-115.PubMed
50.
Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P, Fontanini G, Ugolini C, Camacci T, De Ieso K, et al.: Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003, 13: 765-770. 10.1089/105072503768499662.CrossRefPubMed
51.
Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG, Nikiforov YE: RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003, 88: 2318-2326. 10.1210/jc.2002-021907.CrossRefPubMed
52.
Gaffney RL, Carney JA, Sebo TJ, Erickson LA, Volante M, Papotti M, Lloyd RV: Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland. Am J Surg Pathol. 2003, 27: 494-498. 10.1097/00000478-200304000-00009.CrossRefPubMed
53.
Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET: Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002, 87: 4806-4810. 10.1210/jc.2002-020094.CrossRefPubMed
54.
Coli A, Bigotti G, Zucchetti F, Negro F, Massi G: Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002, 40: 80-87. 10.1046/j.1365-2559.2002.01304.x.CrossRefPubMed
55.
Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Neto G: Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol. 2001, 12: 275-279. 10.1385/EP:12:3:275.CrossRefPubMed
56.
Lavra L, Rinaldo C, Ulivieri A, Luciani E, Fidanza P, Giacomelli L, Bellotti C, Ricci A, Trovato M, Soddu S, et al.: The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS One. 2011, 6: e20665-10.1371/journal.pone.0020665.PubMedCentralCrossRefPubMed
57.
Mai KT, Bokhary R, Yazdi HM, Thomas J, Commons AS: Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology. 2002, 40: 133-142. 10.1046/j.1365-2559.2002.01315.x.CrossRefPubMed
58.
Ozolins A, Narbuts Z, Strumfa I, Volanska G, Gardovskis J: Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg. 2010, 395: 885-891. 10.1007/s00423-010-0690-6.CrossRefPubMed
59.
Liang HS, Zhong YH, Luo ZJ, Huang Y, Lin HD, Luo M, Su HX, Zhou SB, Xie KQ: Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res. 2009, 37: 927-938.CrossRefPubMed
60.
Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A: HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res. 2005, 25: 179-182.PubMed
61.
Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, Nakao A: HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J. 2003, 50: 173-177. 10.1507/endocrj.50.173.CrossRefPubMed
62.
Schmitt AC, Cohen C, Siddiqui MT: Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility. Cancer Cytopathol. 2010, 118: 196-202. 10.1002/cncy.20082.CrossRefPubMed
63.
Bonzanini M, Amadori PL, Sagramoso C, Dalla Palma P: Expression of cytokeratin 19 and protein p63 in fine needle aspiration biopsy of papillary thyroid carcinoma. Acta Cytol. 2008, 52: 541-548. 10.1159/000325595.CrossRefPubMed
64.
Torregrossa L, Faviana P, Filice ME, Materazzi G, Miccoli P, Vitti P, Fontanini G, Melillo RM, Santoro M, Basolo F: CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. Thyroid. 2010, 20: 495-504. 10.1089/thy.2009.0282.CrossRefPubMed
65.
Pennelli G, Mian C, Pelizzo MR, Naccamulli D, Piotto A, Girelli ME, Mescoli C, Rugge M: Galectin-3 cytotest in thyroid follicular neoplasia: a prospective, monoinstitutional study. Acta Cytol. 2009, 53: 533-539. 10.1159/000325381.CrossRefPubMed
66.
Franco C, Martinez V, Allamand JP, Medina F, Glasinovic A, Osorio M, Schachter D: Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol. 2009, 17: 211-215. 10.1097/PAI.0b013e31818935a9.CrossRefPubMed
67.
Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, et al.: Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008, 9: 543-549. 10.1016/S1470-2045(08)70132-3.CrossRefPubMed
68.
Carpi A, Naccarato AG, Iervasi G, Nicolini A, Bevilacqua G, Viacava P, Collecchi P, Lavra L, Marchetti C, Sciacchitano S, Bartolazzi A: Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer. 2006, 95: 204-209. 10.1038/sj.bjc.6603232.PubMedCentralCrossRefPubMed
69.
Kim MJ, Kim HJ, Hong SJ, Shong YK, Gong G: Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol. 2006, 50: 28-34. 10.1159/000325891.CrossRefPubMed
70.
Collet JF, Hurbain I, Prengel C, Utzmann O, Scetbon F, Bernaudin JF, Fajac A: Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br J Cancer. 2005, 93: 1175-1181. 10.1038/sj.bjc.6602822.PubMedCentralCrossRefPubMed
71.
Maruta J, Hashimoto H, Yamashita H, Noguchi S: Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol. 2004, 31: 392-396. 10.1002/dc.20156.CrossRefPubMed
72.
Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A, Kuribayashi T, Hirai K, Nabeshima K, Kotani T: Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol. 2002, 26: 366-372. 10.1002/dc.10111.CrossRefPubMed
73.
Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, et al.: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001, 357: 1644-1650. 10.1016/S0140-6736(00)04817-0.CrossRefPubMed
74.
Rossi ED, Raffaelli M, Minimo C, Mule A, Lombardi CP, Vecchio FM, Fadda G: Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer. 2005, 105: 87-95. 10.1002/cncr.21026.CrossRefPubMed
75.
Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, Cappia S, Conticello S, Papotti M, Orlandi F: Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest. 2004, 27: 311-317.CrossRefPubMed
76.
Mijovic T, Gologan O, Rochon L, Hier M, Black MJ, Young J, Rivera J, Tamilia M, Payne RJ: Fine-needle aspiration biopsy of the thyroid: review of cytopathologic features predictive of malignancy. J Otolaryngol Head Neck Surg. 2009, 38: 348-354.PubMed
77.
de Micco C, Savchenko V, Giorgi R, Sebag F, Henry JF: Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer. 2008, 98: 818-823. 10.1038/sj.bjc.6604194.PubMedCentralCrossRefPubMed
78.
Giorgadze T, Rossi ED, Fadda G, Gupta PK, Livolsi VA, Baloch Z: Does the fine-needle aspiration diagnosis of "Hurthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?. Diagn Cytopathol. 2004, 31: 307-312. 10.1002/dc.20132.CrossRefPubMed
79.
Alaedeen DI, Khiyami A, McHenry CR: Fine-needle aspiration biopsy specimen with a predominance of Hurthle cells: a dilemma in the management of nodular thyroid disease. Surgery. 2005, 138: 650-656. 10.1016/j.surg.2005.06.047. discussion 656–657CrossRefPubMed
80.
Eszlinger M, Paschke R: Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol. 2010, 322: 29-37. 10.1016/j.mce.2010.01.010.CrossRefPubMed
81.
Kato MA, Fahey TJ: Molecular markers in thyroid cancer diagnostics. Surg Clin North Am. 2009, 89: 1139-1155. 10.1016/j.suc.2009.06.012.CrossRefPubMed
82.
Baloch ZW, Abraham S, Roberts S, LiVolsi VA: Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol. 1999, 30: 1166-1171. 10.1016/S0046-8177(99)90033-3.CrossRefPubMed
83.
Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, Raz A, Kubo T: Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol. 2001, 18: 787-792.PubMed
84.
Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ, Laurent G: Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid. 2008, 18: 705-712. 10.1089/thy.2007.0361.CrossRefPubMed
85.
Nga ME, Lim GS, Soh CH, Kumarasinghe MP: HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol. 2008, 36: 550-556. 10.1002/dc.20841.CrossRefPubMed
Metadata
Title
Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis
Authors
Leandro Luongo de Matos
Adriana Braz Del Giglio
Carolina Ogawa Matsubayashi
Michelle de Lima Farah
Auro Del Giglio
Maria Aparecida da Silva Pinhal
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-97

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue

Research

Efficacy of ImageJ in the assessment of apoptosis

Letter to the Editor

Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?

Methodology

Rapid Detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors

Commentary

Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine

Case Report

Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia

Case Report

Isolated cutaneous metastasis of uterine leiomyosarcoma: case report and review of literature